Figure 2.
Improved nail psoriasis with onychomycosis and severe paronychia that persisted although the patient received nine months of canakinumab therapy.
Improved nail psoriasis with onychomycosis and severe paronychia that persisted although the patient received nine months of canakinumab therapy.